产品封面图

Ustekinumab Biosimilar, Human

IL-12 / IL-23 Monoclonal Antibody
收藏
  • ¥1000 - 9600
  • Syd Labs已认证
  • 美国
  • C038P
  • 2026年01月05日
  • Flow cytometry, animal model study
  • Mouse
  • Human
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 免疫原

      Human IL-12 / IL-23

    • 亚型

      Human IgG1 lambda

    • 形态

      Liquid

    • 保存条件

      Store at 2-8℃ and protected from prolonged exposure to light. Avoid freeze/thaw cycles.

    • 克隆性

      Monoclonal Antibody

    • 适应物种

      Human

    • 保质期

      如果保存在2 至 8°C,自收到之日起可保存1个月。如果保存在-20 至 -70°C,自收到之日起可保存 12个月。

    • 抗原来源

      Human IL-12 / IL-23

    • 库存

      1 week

    • 供应商

      青木生物技术(武汉)有限公司

    • 宿主

      Mouse

    • 应用范围

      Flow cytometry, animal model study

    • 浓度

      以实际发货为准

    • 靶点

      IL-12 / IL-23

    • 抗体英文名

      Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody

    • 抗体名

      Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody

    • 规格

      1mg/5mg/20mg

    规格:1mg产品价格:¥1000.0
    规格:5mg产品价格:¥4800.0
    规格:20mg产品价格:¥9600.0
    What is Ustekinumab Biosimilar research grade? Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • monoclonal antibody production fusion

        Fusion is an important procedure to produce monoclonal antibodies (MoAb). PROTOCOL   prepare the culture of myeloma cells and maintain the concentration of the cells at the level of less than 10

    • 【翻译】Development trends for monoclonal antibody cancer therapeutics

      ). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989

    • Rat x Rat Hybridomas

      There is an increasing interest in the preparation of rat � rat hybridomas, because they have been found to be more stable in culture than mouse hybridomas and they secrete consistently high levels (10 �g/mL and above) of monoclonal antibody

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥8768
    深圳欣博盛生物科技有限公司
    2025年07月14日询价
    ¥1000
    青木生物技术(武汉)有限公司
    2026年01月05日询价
    询价
    武汉佰瑞得生物技术有限公司
    2025年07月15日询价
    ¥500
    北京百奥创新科技有限公司
    2025年06月30日询价
    ¥998
    上海碧云天生物技术股份有限公司
    2025年07月01日询价
    Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody
    ¥1000 - 9600